

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

#12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:)	Before the Examiner
)	
Andrew Wallace)	
)	
Serial No. 09/719,362)	Group Art Unit
)	
Filed December 11, 2000)	
)	
METHOD OF GENERATING NUCLEIC)	
ACID HYBRIDS FOR MUTATION)	
ANALYSIS)	
)	
US National Stage of PCT/GB99/01691)	
International Filing Date June 14, 1999)	November 22, 2002

PETITION TO WITHDRAW HOLDING OF ABANDONMENT

Commissioner for Patents
Attn: Anthony Smith
BOX PCT
Washington, D.C. 20231

Sir:

Applicant petitions that the abandonment set forth in the Notification of Abandonment mailed by the Office on July 1, 2002 be withdrawn on the basis that a proper response to the Notification of Missing Requirements dated July 11, 2001 was timely submitted by the Applicant

EXPRESS MAIL LABEL NO.: EV203593419US Date of Mailing: November 22, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR Section 1.10 on the date indicated above and is addressed to the Commissioner for Patents, ATTN: Anthony Smith, BOX PCT, Washington, DC, 20231.


SIGNATURE OF PERSON MAILING

on September 12, 2001. It is believed that no fee is due with regard to submission of this petition; however, to the extent it is determined that a petition fee is required, the Office is hereby authorized to charge deposit account number 23-3030 for any such petition fee.

REMARKS

The following is a chronology of recent events that have transpired in this case:

On July 11, 2001, the PTO issued a Notification of Missing Requirements, which was received by Applicant's attorneys on July 16, 2001. This Notification required that Applicant submit a Sequence Listing pursuant to 37 C.F.R. §1.821-1.825, and set a response period of two months, i.e., expiring on September 11, 2001. A copy of the Notification of Missing Requirements is attached hereto as Exhibit A.

On September 11, 2001, the U.S. Patent and Trademark Office was officially closed, thus extending the period for response to the Notification to September 12, 2001.

On September 12, 2001, Applicant submitted the following as required by the Notification of Missing Requirements: (1) a Submission of Sequence Listing in Paper and Computer-readable Form in Response to Second Notice of Missing Requirements, (2) a paper copy of the Sequence Listing, (3) a diskette containing a computer-readable form of the Sequence Listing, and (4) a return postcard. The Submission of Sequence Listing in Paper and Computer-readable Form included a properly completed Certificate of Mailing. A copy of the submission is attached hereto as Exhibit B. A copy of the return post card showing receipt by the PTO is attached hereto as Exhibit C.

It is worthy of note at this point that the undersigned has just recently become aware of an error on the label of the Sequence Listing diskette submitted September 12, 2001. In

particular, the label set forth the correct inventor name, title, and attorney docket number; however, the Serial No. and Filing Date set forth on the label were incorrect. Because all other information on the submission and on the paper copy of the Sequence Listing was correct, Applicant submits that this inadvertent error on the diskette label should not have caused the submission to have been misplaced.

On July 1, 2002, the PTO mailed a Notification of Abandonment, which was received by Applicant's attorneys on July 8, 2002. A copy of the Notification of Abandonment is attached hereto as Exhibit D.

The reason given in the Notice of Abandonment for the abandonment of the present application is "Applicant has failed to respond to the Notification of Missing Requirements mailed 07/11/2001 within the time period set therein" (see Exhibit D). It is believed that the above documentation clearly shows that Applicant did indeed respond to the Notification by submitting a Submission of Sequence Listing in Paper and Computer-readable Form with Certificate of Mailing by the September 12, 2001 deadline. This Submission was received by the PTO, as evidenced in Exhibit C.

On July 11, 2002, the undersigned placed a telephone call to Barbara A. Campbell, who had issued the Notification of Abandonment, and left a voice message for same. On July 24, 2002, the undersigned placed a second telephone call to Ms. Campbell and conducted a telephone conference with same regarding Applicant's submission of the response on September 12, 2001, which was within the time period for response. At that time, Ms. Campbell requested that we send her file copies of the entire submission plus the date-stamped return postcard by facsimile. The requested materials were transmitted to Ms. Campbell via facsimile on July 25,

2002, and, after subsequent conversations with Ms. Campbell, the undersigned was informed that the case was forwarded to Mr. Anthony Smith in the legal department for further processing.

Upon review, Mr. Smith informed the undersigned on November 6, 2002 that he cannot yet withdraw the holding of abandonment because the prior facsimile transmission to Ms. Campbell was not signed. He then requested that we send a signed Petition under Section 181 to his attention. He also requested that we proceed with submission of a new Sequence Listing for this application. In view thereof, Applicant is hereby submitting the present Petition, and is simultaneously submitting a replacement Sequence Listing to the following address: U.S. Patent and Trademark Office, Box Sequence, P. O. Box 2327, Arlington, VA 22202, with a copy attached hereto as Exhibit E.

In view of the above, Applicant submits that the required Sequence Listing was in fact properly submitted within the response period of two months from the mailing date of the Notification of Missing Requirements (i.e., by September 12, 2001). The Applicant points out that the cover letter accompanying Sequence Listing is dated September 12, 2001, and that the Certificate of Mailing on the cover letter certifies that the cover letter and the Sequence Listing (paper copy and computer-readable form copy) were deposited with the United States Postal Service as first class mail on September 12, 2001.

Accordingly, and in view of the fact that a new substitute Sequence Listing has now been submitted to replace the misplaced Sequence Listing, Applicant petitions that the abandonment set forth in the Notification mailed by the Office on July 1, 2002 be withdrawn.

Acknowledgment of the active status of this application is respectfully requested.

The undersigned, being hereby warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U. S C. 1001, and that willful false

statements may jeopardize the validity of the application or any resulting registration, declares that the facts set forth in this application are true; all statements made of his/her own knowledge are true; and all statements made on information and belief are believed to be true.

Respectfully submitted,

By: _____


Gregory B. Coy

Reg. No. 40,967

Woodard, Emhardt, Naughton

Moriarty & McNett

Bank One Center/Tower

111 Monument Circle, Suite 3700

Indianapolis, IN 46204-5137

(317) 634-3456

PBA/NE/D088165PUS:GBC:191455



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/719362	WALLACE A	7397-2
INTERNATIONAL APPLICATION NO.		
PCT/GB99/01691		
I.A. FILING DATE	PRIORITY DATE	
14 JUN 99	12 JUN 98	

THOMAS Q HENRY
WOODARD EMHARDT NAUGHTON MORIARTY
& MCNETT
111 MONUMENT CIRCLE
3700 BANK ONE TOWER
INDIANAPOLIS, IN 46204

DATE MAILED: 11 JUN 2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EC/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☐ a Designated Office (37 CFR 1.494) ☒ an Elected Office (37 CFR 1.495):
- | | |
|--|---|
| <input checked="" type="checkbox"/> U.S. Basic National Fee. | <input type="checkbox"/> Indication of Small Entity Status. |
| <input checked="" type="checkbox"/> Copy of the international application. | <input type="checkbox"/> Translation of the international application into English. |
| <input checked="" type="checkbox"/> Oath or Declaration of inventor(s). | <input type="checkbox"/> Translation of Article 19 amendments into English. |
| <input type="checkbox"/> Copy of Article 19 amendments. | <input type="checkbox"/> Other: |
| <input type="checkbox"/> Priority Document. | |
| <input checked="" type="checkbox"/> The International Preliminary Examination Report in English and its Annexes, if any. | |
| <input type="checkbox"/> Translation of Annexes to the International Preliminary Examination Report into English. | |
2. ☐ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.
- | | |
|---|---|
| <input type="checkbox"/> U.S. Basic National Fee. | <input type="checkbox"/> Copy of the international application. |
|---|---|
3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:
- | | |
|---|--|
| <input type="checkbox"/> a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date. | |
| <input type="checkbox"/> The current translation is defective for the reasons indicated on the attached Notice of Defective Translation. | |
| <input type="checkbox"/> b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)). | |
| <input type="checkbox"/> c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date. | |
| <input type="checkbox"/> The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917. | |
| <input type="checkbox"/> d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)). | |
4. Additional claim fees of \$_____ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.
5. ☒ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

8-11-01
ENTERED
8-11-01

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this response.

Enclosed: ☐ PCT/DO/EO/917 ☐ Notice of Defective Translation
☐ PTO-875 ☒ PCT/DO/EO/920

Barbra Campbell, Paralegal

FORM PCT/DO/EO/905 (March 2001)

Telephone: 703 305-3631



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/719362	WALLACE	A 7397-2
INTERNATIONAL APPLICATION NO.		
PCT/GB99/01691		
I.A. FILING DATE		PRIORITY DATE
14 JUN 99		12 JUN 98

THOMAS Q HENRY
WOODARD EMHARDT NAUGHTON MORIARTY & MCNETT
111 MONUMENT CIRCLE
3700 BANK ONE TOWER
INDIANAPOLIS, IN 46204

DATE MAILED: JUN 10 2001

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☒ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☒ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ Other: _____

APPLICANT MUST PROVIDE:

- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:**

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

Barbara A. Campbell

Telephone: 703-305-3631

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:)
 Andrew Wallace)
 Serial No. 09/719,362)
 Filed December 11, 2000)
 METHOD OF GENERATING NUCLEIC)
 ACID HYBRIDS FOR MUTATION)
 ANALYSIS)
 US National Stage of PCT/GB99/01691)
 International Filing Date June 14, 1999)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on

September 12, 2001

(Date of Deposit)

Gregory B. Coy

Name of Registered Representative

Signature

September 12, 2001

Date of Signature

September 12, 2001

**SUBMISSION OF SEQUENCE LISTING IN PAPER AND
 COMPUTER READABLE FORM IN RESPONSE TO SECOND
 NOTICE OF MISSING REQUIREMENTS**

Commissioner of Patents
 Washington, D.C. 20231

Sir:

In response to the notice of missing requirements dated July 11, 2001, Applicant submits herewith a Sequence Listing on paper and the required Sequence Listing in computer readable form. No fees are believed to be due; however, if any fees are deemed necessary, the Commissioner is hereby authorized to charge payment of any additional fees associated with this application or credit any overpayment to Deposit Account No. 23-3030.

IN THE SPECIFICATION

Please enter the attached new Sequence Listing, pages 1-12, into the application.

Please amend the paragraph extending from page 7, line 24, to page 8, line 6, to read as follows:

5'tcatattagccgctgcattgcc-a-specific seq 3' (SEQ ID NO:32)

5'ggcaatgcagcggctaataatga-a-specific seq 3' (SEQ ID NO:33)

5'agccactacccaaactcctgt-a-specific seq 3' (SEQ ID NO:34)

5'acaggagtttggttagtggt-a-specific seq 3' (SEQ ID NO:35)

5'tgtctcactgaacctgcctacct--a-specific seq 3' (SEQ ID NO:36)

5'aggtaggcaggttcagtgcagaca-a-specific seq 3' (SEQ ID NO:37)

5'cctcattaccggctgtcagactg-a-specific seq 3' (SEQ ID NO:38)

5'cagtctgacagccgtaataagg-a-specific seq 3' (SEQ ID NO:39)

REMARKS


Entry of the above-amendments is respectfully requested. Included in this communication is an ADDENDUM that provides a marked-up version of the amended portion of the specification to delineate the amendments made in accordance with 37 C.F.R. § 1.121 (b)(1).

In accordance with 37 C.F.R. § 1.821 et seq., applicant hereby submits the Sequence Listing, indicated as new pages 1 through 12, along with a computer readable form of the Sequence Listing. The information recorded in computer readable form is identical to the paper copy of the Sequence Listing, except that the paper copy includes page numbers and the computer readable form does not. The above amendments to the specification are also made to insert reference to SEQ ID numbers. The present amendment is supported in the application as filed, and no new matter is introduced by these amendments.

Entry of the above amendments and examination of the application are
respectfully requested.

Respectfully submitted,

By: _____


Gregory B. Coy
Reg. No. 40,967
Woodard, Emhardt, Naughton
Moriarty & McNett
Bank One Center/Tower
111 Monument Circle, Suite 3700
Indianapolis, IN 46204-5137
(317) 634-3456

PBA/NE/D088165PUS.GBC:141674

ADDENDUM

IN THE SPECIFICATION

5'tcatattagccgctgcattgcc-a-specific seq 3' (SEQ ID NO:32)

5'ggcaatgcagcggctaataatga-a-specific seq 3' (SEQ ID NO:33)

5'agccactacccaaactcctgt-a-specific seq 3' (SEQ ID NO:34)

5'acaggagtttgggtagtggt-a-specific seq 3' (SEQ ID NO:35)

5'tgtctcactgaacctgcctacct--a-specific seq 3' (SEQ ID NO:36)

5'aggtaggcaggttcagtgagaca-a-specific seq 3' (SEQ ID NO:37)

5'cctcattaccggctgtcagactg-a-specific seq 3' (SEQ ID NO:38)

5'cagtctgacagccgtaatgagg-a-specific seq 3' (SEQ ID NO:39)

SEQUENCE LISTING

<110> WALLACE, ANDREW
CENTRAL MANCHESTER HEALTHCARE NHS TRUST

<120> NUCLEIC ACIDS

<130> 7397-2

<140> 09/719,362

<141> 2000-12-11

<150> PCT/GB99/01691

<151> 1999-06-14

<150> 9812674.1 GB

<151> 1998-06-12

<160> 39

<170> PatentIn Ver. 2.0

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER
SEQUENCE FOR AMPLIFICATION OF NF2

<400> 1

gtggcaaaca ataccaaatt tac

23

<210> 2

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 12

<222> LocationTo : 12

Other Information : Unknown

CDSJoin : No

<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 2

tgtctcactg anacctgcct acctacccat aaaggaatgt aaaccaac

48

<210> 3
 <211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: PRIMER
 SEQUENCES FOR AMPLIFICATION OF NF2

 <400> 3
 aggtaggcag gttcagtgag acaaccgctc tccacccatc tcac 44

 <210> 4
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: PRIMER
 SEQUENCES FOR AMPLIFICATION OF NF2

 <400> 4
 agccactacc caaactcctg tatggccctc actcagtc tc 42

 <210> 5
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: PRIMER
 SEQUENCES FOR AMPLIFICATION OF NF2

 <400> 5
 acaggagttt gggtagtggc tagagcctca gctggcgctt ac 42

 <210> 6
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: PRIMER
 SEQUENCES FOR AMPLIFICATION OF NF2

 <400> 6
 tcatattagc cgctgcattg ccagatctgc tggacccatc tgc 43

 <210> 7
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: PRIMER
 SEQUENCES FOR AMPLIFICATION OF NF2

<400> 7
 ggcaatgcag cggctaatat gaaaggctgt cggactgaaa ctg 43
 <210> 8
 <211> 49
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: PRIMER
 SEQUENCES FOR AMPLIFICATION OF NF2
 <400> 8
 cctcattacc ggctgtcaga ctgattctca gaaaagctac cattatcag 49
 <210> 9
 <211> 47
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: PRIMER
 SEQUENCES FOR AMPLIFICATION OF NF2
 <400> 9
 cagtctgaca gccggtaatg aggaggcagt gaagtaaatt tgtggat 47
 <210> 10
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: PRIMER
 SEQUENCES FOR AMPLIFICATION OF NF2
 <400> 10
 aggccaggac tgaccacaca 20
 <210> 11
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: PRIMER
 SEQUENCES FOR AMPLIFICATION OF NF2
 <400> 11
 catgtgtagg ttttttatatt tgctc 25
 <210> 12
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Description of Artificial Sequence: PRIMER SEQUENCES FOR AMPLIFICATION OF NF2	
<400> 12 tgaccacaca gtgacatcat cag	23
<210> 13 <211> 21 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: PRIMER TO AMPLIFY hMLH1 GENE	
<400> 13 gatgtttcag tctcagccat g	21
<210> 14 <211> 49 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: PRIMER TO AMPLIFY hMLH1 GENE	
<400> 14 tcatattagc cgctgcattg ccaggaatga taaaccaaga taataaatg	49
<210> 15 <211> 49 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: PRIMER TO AMPLIFY hMLH1 GENE	
<400> 15 ggcaatgcag cggctaatat gaattctttt gtaatgtttg agttttgag	49
<210> 16 <211> 43 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: PRIMER TO AMPLIFY hMLH1 GENE	
<400> 16 agccactacc caaactcctg tacctgtgag tggatttccc atg	43
<210> 17 <211> 44 <212> DNA	

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 17
acaggagttt gggtagtggc taccctcaga cagttttgaa ctgg 44

<210> 18
<211> 46
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 18
tctctcactg aatccgccta cctacttggt tgaggagttt ggtgct 46

<210> 19
<211> 48
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 19
aggtaggcgg attcagtgag agaaccctcc cactatctaa ggtaattg 48

<210> 20
<211> 44
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 20
taacattcca ggctgtcgga ctgaagtagc tggatgagaa gcgc 44

<210> 21
<211> 50
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 21
cagtccgaca gcctggaatg ttaatttaat acagactttg ctaccaggac 50

<210> 22
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: PRIMER TO
 AMPLIFY hMLH1 GENE

 <400> 22
 taaagagtag ctgtactttt cccaa 25

 <210> 23
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: PRIMER TO
 AMPLIFY hMLH1 GENE

 <400> 23
 taaatccttg tgtcttctgc tg 22

 <210> 24
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: PRIMER TO
 AMPLIFY hMLH1 GENE

 <400> 24
 aagccatacc tgggggttg 18

 <210> 25
 <211> 256
 <212> DNA
 <213> Unknown

 <220>
 <223> Description of Unknown Organism:+UNKNOWN

 <400> 25
 tctgtgtgac tactcctggt gtagctttaa aatagcttta ctgtttgtaa aatgatgcat 60
 aattataaaa gtggcaaaca ataccaaatt tacttcatgt gtaggttttt tattttgctc 120
 tatttttttg taggtaataa atctgtatca gatgactccg gaaatgtggg aggagagaat 180
 tactgcttggt tacgcagagc accgaggccg agccaggtga ggcccattca ttgttggttt 240
 acattccttt atgggc 256

 <210> 26
 <211> 240
 <212> DNA
 <213> Unknown

 <220>

<223> Description of Unknown Organism:+UNKNOWN

<400> 26

```
gaatgcttga tttggtggcc caccgctct ccacccatct cacttagctc caatgacagt 60
gtcttccgtt ctccccacag ggatgaagct gaaatggaat atctgaagat agctcaggac 120
ctggagatgt acggtgtgaa ctactttgca atccgggtgt gttgaaacct ctctgagctc 180
cttgtgtagt agacagagac tgagtgaggg ccaggactgc taaaatggtt acttcttcat 240
```

<210> 27

<211> 387

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:+UNKNOWN

<400> 27

```
tctgtggacc tgctgaactg cacatgtgac agtgtgtgcc agattctttg gaagggttgaa 60
taaaattttg agcctcagct ggcgcttaca gtagctgttc ttattggatc cacagaataa 120
aaagggcaca gagctgctgc ttggagtggg tgccctgggg cttcacattt atgaccctga 180
gaacagactg accccaaga tctccttccc gtggaatgaa atccgaaaca tctcgtacag 240
tgacaaggag gtaggacatg tgtgtactgc agatgggtcc agcagatctt tccctgtctg 300
ccccctcac tggagcctcc ccagccaggg catctccttg ttattcatag agtcctttaa 360
ttcccaggct ttgaggggtg ggttggtt 387
```

<210> 28

<211> 315

<212> DNA

<213> Unknown

<220>

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 54

LocationTo : 54

Other Information : Unknown

CDSJoin : No

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 68

LocationTo : 68

Other Information : Unknown

CDSJoin : No

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 112

LocationTo : 112

Other Information : Unknown

CDSJoin : No

<223> Description of Unknown Organism:+UNKNOWN

<400> 28

```
gacttggtgc tcctaattcc ctgaggttta gtgcctggat actgggaagc cagnacaagg 60
gcataacntc atgctgggtct gtggccagtg tggttgcgca tttgtggaat tnccaattgc 120
tggtaacatt ccaggctgtc ggactgaaac tgtgttctgc ttcattcttc cagtttacta 180
ttaaaccact ggataagaaa attgatgtct tcaagtttaa ctcctcaaag cttcgtgtta 240
ataagctggg aagttgagat cctggtaagt tgagatcctg gttttcatta ctgataatgg 300
tagcttttct gagaa                                     315
```

<210> 29

<211> 269

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:+UNKNOWN

<400> 29

```
tgctacctgc aagagctcaa actgctatgg cactagtggg ccagtaggca gtgaagtaaa 60
tttgtggata ttaacctttt tgtctgcttc tgtggccaca gattctccag ctatgtatcg 120
ggaaccatga tctatttatg aggagaagga aagccgattc tttggaagtt cagcagatga 180
aagcccaggc cagggaggag aaggctagaa agcaggtgag cacaaccttg ttttaactga 240
tgatgtcact gtgtggtcag tcctggcct                                     269
```

<210> 30

<211> 579

<212> DNA

<213> Unknown

<220>

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 6

LocationTo : 6

Other Information : Unknown

CDSJoin : No

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 375

LocationTo : 375

Other Information : Unknown

CDSJoin : No

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 537
LocationTo : 537
Other Information : Unknown
CDSJoin : No

<223> Description of Unknown Organism:SEQUENCE OF NF2
GENE DETERMINED BY USE OF PRIMER 11

<400> 30
tatccntttg gtaggtaata aatctgtatc agatgactcc ggaaatgtgg gaggagagaa 60
ttactgcttg gtacgcagag caccgaggcc gagccagggtg aggcccatc attgttggtt 120
tacattcctt tatgggtagg taggcagggt cagtgcagaca accgctctcc acccatctca 180
cttagctcca atgacagtgt cttccgttct cccacacagg atgaagctga aatggaatat 240
ctgaagatag ctgaggacct ggagatgtac ggtgtgaact actttgcaat cggggtgtgt 300
tgaaacctct ctgagctcct tgtgtagtag acagagactg agtgaggggc atacaggagt 360
ttgggtagtg gctanagcct cagctggcgc ttacagttagc tgttcttatt ggatccactg 420
aataaaaagg gcacagagct gctgcttggg gtggatggcc tggggcttca catttatgac 480
cctgagaaca gactgacccc caagatctcc ttcccggtga atgaaatccg aaacatntcg 540
tacagtgaca aggaggtagg acatgtgtgt actgcaaat 579

<210> 31
<211> 586
<212> DNA
<213> Unknown

<220>

Feature

Sequence:

<221> Unsure
<222> LocationFrom : 581
<222> LocationTo : 581
Other Information : Unknown
CDSJoin : No

<223> Description of Unknown Organism:SEQUENCE OF NF2
GENE DETERMINED USING PRIMER 12

<400> 31
taaaacaagg ttgtgctcac ctgcttttcta gccttctcct ccctggcctg ggcttttcac 60
tgctgaactt ccaaagaatc ggcttttcctt ctctcataa atagatcatg gttcccgata 120
catagctgga gaatctgtgg ccacagaagc agacaaaaag gttaatatcc acaaatttac 180
ttcactgcct cctcattacc ggctgtcaga ctgattctca gaaaagctac cattatcagt 240
aatgaaaacc aggatctcaa cttaccagct tattaacacg aagctttgag gagttaaaact 300
tgaagacatc aattttctta tccagtgggt taatagtaaa ctggaagaat gaagcagaac 360
acagtttcag tccgacagcc tttcatatta gccgctgcat tgccagatct gctggaccca 420
tctgcagtac acacatgtcc tacctccttg tcaactgtac agatgtttcg gatttcattc 480
cacgggaagg agatcttggg ggtcaagtct gttctcaggg cataaatgtg aagccccagg 540
gcatccactt caagcagcag ctctggccct ttttattcag nggatc 586

<210> 32
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:LINKER PRIMER
 SEQUENCE

 <220>
 <221> misc_feature
 <222> (23)
 <223> LINKED TO PRIMING PORTION OF LINKER PRIMER

 <400> 32
 tcatattagc cgctgcattg cca 23

 <210> 33
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:LINKER PRIMER
 SEQUENCE

 <220>
 <221> misc_feature
 <222> (23)
 <223> LINKED TO PRIMING PORTION OF LINKER PRIMER

 <400> 33
 ggcaatgcag cggctaataat gaa 23

 <210> 34
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:LINKER PRIMER
 SEQUENCE

 <220>
 <221> misc_feature
 <222> (22)
 <223> LINKED TO PRIMING PORTION OF LINKER PRIMER

 <400> 34
 agccactacc caaactcctg ta 22

 <210> 35
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:LINKER PRIMER
 SEQUENCE

 <220>

<221> misc_feature
<222> (22)
<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 35
acaggagttt gggtagtggc ta

22

<210> 36
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>
<221> misc_feature
<222> (24)
<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 36
tgtctcactg aacctgccta ccta

24

<210> 37
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>
<221> misc_feature
<222> (24)
<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 37
aggtaggcag gttcagtga acaa

24

<210> 38
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>
<221> misc_feature
<222> (24)
<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 38
cctcattacc ggctgtcaga ctga

24

<210> 39
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>
<221> misc_feature
<222> (24)
<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 39
cagtctgaca gccggtaatg agga

24

WALLACE, Andrew
Title: METHOD OF GENERATING NUCLEIC
ACID HYBRIDS FOR MUTATION ANALYSIS
Recorded on September 12, 2001
Serial No. 09/230,572
Filed: December 13, 1999
Docket No. 7397-2

Matter No. 7397-2

Initials: TOH/GBC/pab 9/12/2001

PLEASE RETURN THIS CARD

(☒) Patent () Trademark
() Copyright

Serial No. 09/719,362
Applicant: WALLACE, Andrew
METHOD OF GENERATING NUCLEIC
ACID HYBRIDS FOR MUTATION
ANALYSIS

Receipt of the attached is
acknowledged.

() Application
() Check for \$ _____
() _____ sheets of drawing(s)
() Small Entity Declaration
() Declaration & Power of Atty.
() Assignment
() Amendment
() Req. for Extension of Time
() Specimens
() Information Disclosure Statement
☒ Subm. of Seq. Listing/
() Response to 2nd Not. of
() Missing Parts

Matter No. 7397-2

Initials: TOH/GBC/pab 9/12/2001

PLEASE RETURN THIS CARD

(☒) Patent () Trademark
() Copyright

Serial No. 09/719,362
Applicant: WALLACE, Andrew
METHOD OF GENERATING NUCLEIC
ACID HYBRIDS FOR MUTATION
ANALYSIS

Receipt of the attached is
acknowledged.

- () Application
- () Check for \$ _____
- () _____ sheets of drawing(s)
- () Small Entity Declaration
- () Declaration & Power of Atty.
- () Assignment
- () Amendment
- () Req. for Extension of Time
- () Specimens
- () Information Disclosure Statement
- ☒ Subm. of Seq. Listing/
- () Response to 2nd Not. of
- () Missing Parts

533 Rec'd PCT/PTO 15 SEP 2001



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/719,362	Andrew Wallace	7397-2

INTERNATIONAL APPLICATION NO.

PCT/GB99/01691

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

06/14/1999

Thomas Q Henry
Woodard Emhardt Naughton Moriarty & Mcnett
111 Monument Circle
3700 Bank One Tower
Indianapolis, IN 46204

CONFIRMATION NO. 7018

371

ABANDONMENT/TERMINATION
LETTER

OC00000008378897

Date Mailed: 07/01/2002

NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as a Designated Office (37 CFR 1.494), has made the following determination:

- Applicant has failed to respond to the notification of MISSING REQUIREMENTS, mailed 07/11/2001 within the time period set therein.

8-102

Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.494, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 3 - OFFICE COPY

FORM PCT/DO/EO/909 (371 Abandonment Notice)

RECEIVED

JUL - 8 2001

Woodard, Emhardt, Naughton,
Moriarty & McNett